COMMUNIQUÉS West-GlobeNewswire

Altimmune Announces Second Quarter 2026 Financial Results and Business Update
12/08/2026
Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and [...]
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
12/08/2026
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established [...]
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
12/08/2026
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization Partnership with [...]
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
12/08/2026
Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025 Adjusted EBITDA more than doubled year-over-year to $3.5 million, with margin expanding to 20% Remaining performance [...]
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
12/08/2026
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs [...]
ADARx Pharmaceuticals Expands Leadership Team with Board and Executive Appointments
12/08/2026
– Ying Huang, Ph.D. appointed to Board of Directors, bringing deep experience spanning executive public biotech leadership, Wall Street and big pharma R&D – – Robert Ackles joins as Chief People Officer, bringing [...]
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
12/08/2026
CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Reflect Scientific Reports More Than $1.4 Million in Freezer-System Sales to Biopharmaceutical Customers
12/08/2026
OREM, Utah, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF) today announced more than $1.4 million in delivered commercial freezer-system sales to six biopharmaceutical companies during the [...]
Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
12/08/2026
Milestone strengthens manufacturing flexibility and supports pivotal study readiness BURLINGTON, Mass, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, [...]
Solana Company to Release Second Quarter 2026 Operating Results on August 14, 2026
12/08/2026
PHILADELPHIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury, infrastructure, and services company providing institutional access to [...]
MUHC Foundation President and CEO Marie-Hélène Laramée appointed to Women’s Health Collective Canada Board of Directors
12/08/2026
Laramée’s appointment strengthens Quebec’s voice in the national movement to close gaps in women’s health research, care, and leadership MONTREAL, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The McGill University Health Centre ( [...]
Marie-Hélène Laramée, présidente-directrice générale de la Fondation du CUSM, nommée au conseil d’administration de l’Association canadienne pour l’équité en santé des femmes
12/08/2026
La nomination de Marie-Hélène Laramée renforce la voix du Québec au sein du mouvement national. Son objectif : combler les lacunes en matière de recherche, de soins et de leadership en santé des femmes MONTREAL, 12 août [...]
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
12/08/2026
HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule [...]
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
12/08/2026
Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 CNTY-813 preclinical data from [...]
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
12/08/2026
Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Society (ERS) Congress, [...]
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
12/08/2026
Commercial launch supported by a dedicated national sales force, payer and institutional access, and multi-channel marketing campaign supporting adoption of REZENOPY ™ Targeting continued commercial execution through [...]
Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission
12/08/2026
Final histology and laboratory analyses support the study’s safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a [...]
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
12/08/2026
TEL AVIV, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company [...]
Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes
12/08/2026
Agreement combines Austrianova’s Cell-in-a-Box® technology with San Raffaele Hospital’s stem cell-derived beta cell expertise through a research collaboration with Avaí Bio and Austrianova’s JV Company, Insulinova, [...]

Pages